相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The PI3K/AKT Pathway as a Target for Cancer Treatment
Ingrid A. Mayer et al.
ANNUAL REVIEW OF MEDICINE, VOL 67 (2016)
Drugging PI3K in cancer: refining targets and therapeutic strategies
Timothy A. Yap et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Current treatment strategies for inhibiting mTOR in cancer
Francesca Chiarini et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
Andrea Rocca et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus
Pengda Liu et al.
NATURE (2014)
The Enhanced In Vivo Activity of the Combination of a MEK and a PI3K Inhibitor Correlates with [18F]-FLT PET in Human Colorectal Cancer Xenograft Tumour-Bearing Mice
Emma J. Haagensen et al.
PLOS ONE (2013)
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
E. J. Haagensen et al.
BRITISH JOURNAL OF CANCER (2012)
Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma
Christine K. Cheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
Brian J. Lannutti et al.
BLOOD (2011)
Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301
Huw D. Thomas et al.
EUROPEAN JOURNAL OF CANCER (2011)
Synthesis and biological evaluation of 5-substituted O-4-alkylpyrimidines as CDK2 inhibitors
Francesco Marchetti et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2010)
PI3K and mTOR inhibitors - a new generation of targeted anticancer agents
Saskia Brachmann et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
Thomas S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Common corruption of the mTOR signaling network in human tumors
S Menon et al.
ONCOGENE (2009)
Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms
A. Satyanarayana et al.
ONCOGENE (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis
Subbareddy Maddika et al.
JOURNAL OF CELL SCIENCE (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils
AM Condliffe et al.
BLOOD (2005)
Restraining PI3K: mTOR signalling goes back to the membrane
LS Harrington et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2
KL Sayle et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
4-alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 2
V Mesguiche et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor
TG Davies et al.
NATURE STRUCTURAL BIOLOGY (2002)
Identification of PTEN mutations in metastatic melanoma specimens
JT Çelebi et al.
JOURNAL OF MEDICAL GENETICS (2000)
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
CE Arris et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
分享论文
